Cephalon Inc. said Friday that it has received orphan drugdesignation from the Food and Drug Administration forMyotrophin to treat amyotrophic lateral sclerosis.
Myotrophin recombinant IGF-1 (insulin-like growth factor) is aprotein that stimulates the growth and prolongs the life ofmotor neurons.
ALS, or Lou Gehrig's disease, is a progressive nervous systemdisorder affecting about 30,000 people in the United States.There is no known cause or cure.
The West Chester, Pa., company recently received a notice ofallowance from the Patent and Trademark Office on a patentapplication for the use of IGF-1 to treat ALS. Cephalon(NASDAQ:CEPH) intends to file an investigational new drugapplication with the Food and Drug Administration in thesecond quarter of 1992.
(c) 1997 American Health Consultants. All rights reserved.